A novel prognostic nomogram for predicting survival in diffuse pleural mesothelioma

被引:4
作者
Aksoy, Yagiz [1 ,2 ,3 ]
Chou, Angela [1 ,2 ,3 ]
Mahjoub, Mahiar [1 ,2 ,3 ]
Sheen, Amy [1 ,2 ]
Sioson, Loretta [1 ,2 ,3 ]
Ahadi, Mahsa S. [1 ,2 ,3 ]
Gill, Anthony J. [1 ,2 ,3 ]
Fuchs, Talia L. [1 ,3 ,4 ]
机构
[1] Royal North Shore Hosp, Kolling Inst Med Res, Canc Diag & Pathol Grp, St Leonards, NSW, Australia
[2] Royal North Shore Hosp, NSW Hlth Pathol, Dept Anat Pathol, Sydney, NSW, Australia
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[4] Douglass Hanly Moir Pathol, 14 Giffnock Ave, Macquarie Pk, NSW 2113, Australia
关键词
Mesothelioma; prognosis; nomogram; PHASE-II TRIALS; MALIGNANT MESOTHELIOMA; EXPRESSION; OUTCOMES; PNEUMONECTOMY; CHEMOTHERAPY; ASSOCIATION; MULTICENTER; IPILIMUMAB; NIVOLUMAB;
D O I
10.1016/j.pathol.2022.11.009
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Recent advances in the management of diffuse pleural me-sothelioma (DPM) have increased interest in prognostication and risk stratification on the basis that maximum benefit of combination immunotherapy appears to be seen in patients who otherwise would have the worst prognosis. Various grading schemes have been proposed, including the recently published Mesothelioma Weighted Grading Scheme (MWGS). However, predictive modelling using deep learning algorithms is increasingly regarded as the gold standard in prognostication. We therefore sought to develop and validate a prognostic nomogram for DPM. Data from 369 consecutive patients with DPM were used as independent training and validation cohorts to develop a prognostic tool that included the following variables: age, sex, histological type, nuclear atypia, mitotic count, ne-crosis, and BAP1 immunohistochemistry. Patients were stratified into four risk groups to assess model discrimi-nation and calibration. To assess discrimination, the area -under-the-curve (AUC) of a receiver-operator-curve (ROC), concordance-index (C-index), and dissimilarity index (D-index) were calculated. Based on the 5-year ROC analysis, the AUC for our model was 0.75. Our model had a C-index of 0.67 (95% CI 0.53-0.79) and a D-index of 2.40 (95% CI 1.69-3.43). Our prognostic nomogram for DPM is the first of its kind, in-corporates well established prognostic markers, and dem-onstrates excellent predictive capability. As these factors are routinely assessed in most pathology laboratories, it is hoped that this model will help inform prognostication and difficult management decisions, such as patient selection for novel therapies. This nomogram is now freely available online at: https://nomograms.shinyapps.io/Meso_Cox_ML/.
引用
收藏
页码:449 / 455
页数:7
相关论文
共 45 条
[1]   Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology [J].
Andrici, Juliana ;
Sheen, Amy ;
Sioson, Loretta ;
Wardell, Kathryn ;
Clarkson, Adele ;
Watson, Nicole ;
Ahadi, Mahsa S. ;
Farzin, Mahtab ;
Toon, Christopher W. ;
Gill, Anthony J. .
MODERN PATHOLOGY, 2015, 28 (10) :1360-1368
[2]   Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma [J].
Anraku, Masaki ;
Cunningham, Kristopher S. ;
Yun, Zhihong ;
Tsao, Ming-Sound ;
Zhang, Li ;
Keshavjee, Shaf ;
Johnston, Michael R. ;
de Perrot, Marc .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2008, 135 (04) :823-829
[3]   First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial [J].
Baas, Paul ;
Scherpereel, Arnaud ;
Nowak, Anna K. ;
Fujimoto, Nobukazu ;
Peters, Solange ;
Tsao, Anne S. ;
Mansfield, Aaron S. ;
Popat, Sanjay ;
Jahan, Thierry ;
Antonia, Scott ;
Oulkhouir, Youssef ;
Bautista, Yolanda ;
Cornelissen, Robin ;
Greillier, Laurent ;
Grossi, Francesco ;
Kowalski, Dariusz ;
Rodriguez-Cid, Jeronimo ;
Aanur, Praveen ;
Oukessou, Abderrahim ;
Baudelet, Christine ;
Zalcman, Gerard .
LANCET, 2021, 397 (10272) :375-386
[4]   Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival [J].
Beebe-Dimmer, Jennifer L. ;
Fryzek, Jon P. ;
Yee, Cecilia L. ;
Dalvi, Tapashi B. ;
Garabrant, David H. ;
Schwartz, Ann G. ;
Gadgeel, Shirish .
CLINICAL EPIDEMIOLOGY, 2016, 8 :743-750
[5]   Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study [J].
Brcic, Luka ;
Klikovits, Thomas ;
Megyesfalvi, Zsolt ;
Mosleh, Berta ;
Sinn, Katharina ;
Hritcu, Richard ;
Laszlo, Viktoria ;
Cufer, Tanja ;
Rozman, Ales ;
Kern, Izidor ;
Mohorcic, Katja ;
Jakopovic, Marko ;
Samarzija, Miroslav ;
Seiwerth, Sven ;
Kolek, Vitezslav ;
Fischer, Ondrej ;
Jakubec, Petr ;
Skarda, Jozef ;
Gieszer, Balazs ;
Hegedus, Balazs ;
Fillinger, Janos ;
Renyi-Vamos, Ferenc ;
Buder, Anna ;
Bilecz, Agnes ;
Berger, Walter ;
Grusch, Michael ;
Hoetzenecker, Konrad ;
Klepetko, Walter ;
Hoda, Mir Alireza ;
Filipits, Martin ;
Dome, Balazs .
TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (04) :1594-1607
[6]   Mesothelioma: Scientific clues for prevention, diagnosis, and therapy [J].
Carbone, Michele ;
Adusumilli, Prasad S. ;
Alexander, H. Richard, Jr. ;
Baas, Paul ;
Bardelli, Fabrizio ;
Bononi, Angela ;
Bueno, Raphael ;
Felley-Bosco, Emanuela ;
Galateau-Salle, Francoise ;
Jablons, David ;
Mansfield, Aaron S. ;
Minaai, Michael ;
de Perrot, Marc ;
Pesavento, Patricia ;
Rusch, Valerie ;
Severson, David T. ;
Taioli, Emanuela ;
Tsao, Anne ;
Woodard, Gavitt ;
Yang, Haining ;
Zauderer, Marjorie G. ;
Pass, Harvey, I .
CA-A CANCER JOURNAL FOR CLINICIANS, 2019, 69 (05) :402-429
[7]   Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial [J].
Disselhorst, Maria J. ;
Quispel-Janssen, Josine ;
Lalezari, Ferry ;
Monkhorst, Kim ;
de Vries, Jeltje F. ;
van der Noort, Vincent ;
Harms, Emmy ;
Burgers, Sjaak ;
Baas, Paul .
LANCET RESPIRATORY MEDICINE, 2019, 7 (03) :260-270
[8]   Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma [J].
Doi, Hiroshi ;
Kuribayashi, Kozo ;
Kitajima, Kazuhiro ;
Yamakado, Koichiro ;
Kijima, Takashi .
CLINICAL LUNG CANCER, 2020, 21 (01) :66-+
[9]   Loss of expression of BAP1 predicts longer survival in mesothelioma [J].
Farzin, Mahtab ;
Toon, Christopher W. ;
Clarkson, Adele ;
Sioson, Loretta ;
Watson, Nicole ;
Andrici, Juliana ;
Gill, Anthony J. .
PATHOLOGY, 2015, 47 (04) :302-307
[10]   Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial [J].
Fennell, Dean A. ;
Ewings, Sean ;
Ottensmeier, Christian ;
Califano, Raffaele ;
Hanna, Gerard G. ;
Hill, Kayleigh ;
Danson, Sarah ;
Steele, Nicola ;
Nye, Mavis ;
Johnson, Lucy ;
Lord, Joanne ;
Middleton, Calley ;
Szlosarek, Peter ;
Chan, Sam ;
Gaba, Aarti ;
Darlison, Liz ;
Wells-Jordan, Peter ;
Richards, Cathy ;
Poile, Charlotte ;
Lester, Jason F. ;
Griffiths, Gareth .
LANCET ONCOLOGY, 2021, 22 (11) :1530-1540